» Articles » PMID: 39096385

Predictors of Improvement in Disease Activity in Childhood and Adolescent Crohn's Disease: an Analysis of Age, Localization, Initial Severity and Drug Therapy - Data from the Saxon Registry for Inflammatory Bowel Disease in Children in Germany...

Overview
Journal Eur J Pediatr
Specialty Pediatrics
Date 2024 Aug 3
PMID 39096385
Authors
Affiliations
Soon will be listed here.
Abstract

The escalating worldwide prevalence of Crohn's disease (CD) among children and adolescents, coupled with a trend toward earlier onset, presents significant challenges for healthcare systems. Moreover, the chronicity of this condition imposes substantial individual burdens. Consequently, the principal objective of CD treatment revolves around rapid inducing remission. This study scrutinizes the impact of age, gender, initial disease localization, and therapy on the duration to achieve disease activity amelioration. Data from the Saxon Pediatric IBD Registry in Germany were analyzed over a period of 15 years. In addition to descriptive methods, logistic and linear regression analyses were conducted to identify correlations. Furthermore, survival analyses and Cox regressions were utilized to identify factors influencing the time to improvement in disease activity. These effects were expressed as Hazard Ratios (HR) with 95% confidence intervals. Data on the clinical course of 338 children and adolescents with CD were available in the registry. The analyses showed a significant correlation between a young age of onset and the severity of disease activity. It was evident that treatment with anti-TNF (Infliximab) was associated with a more favorable prognosis in terms of the time required for improvement in disease activity. Similarly, favorable outcomes were observed with the combination therapies of infliximab with enteral nutrition therapy and Infliximab with immunosuppressants.Conclusion: Our analysis of data from the Saxon Pediatric IBD Registry revealed that the timeframe for improvement of disease activity in pediatric Crohn's disease is influenced by several factors. Specifically, patient age, treatment modality, and initial site of inflammation were found to be significant factors. The study provides important findings that underline the need for individualized treatment.

Citing Articles

Outcome of pediatric inflammatory bowel disease in Asian children: a multinational 1-year follow-up study.

Tanpowpong P, Treepongkaruna S, Huang J, Huang J, Chew K, Mercado K Clin Exp Pediatr. 2024; 68(3):247-256.

PMID: 39533716 PMC: 11884952. DOI: 10.3345/cep.2024.01144.

References
1.
Walters T, Kim M, Denson L, Griffiths A, Dubinsky M, Markowitz J . Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2013; 146(2):383-91. DOI: 10.1053/j.gastro.2013.10.027. View

2.
Gasparetto M, Guariso G, Visona Dalla Pozza L, Ross A, Heuschkel R, Zilbauer M . Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC Gastroenterol. 2016; 16:35. PMC: 4791934. DOI: 10.1186/s12876-016-0455-y. View

3.
Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J . Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8(10):1179-207. DOI: 10.1016/j.crohns.2014.04.005. View

4.
Kern I, Schoffer O, Kiess W, Henker J, Laass M, Winkler U . Incidence trends of pediatric onset inflammatory bowel disease in the years 2000-2009 in Saxony, Germany-first results of the Saxon Pediatric IBD Registry. PLoS One. 2021; 16(1):e0243774. PMC: 7781364. DOI: 10.1371/journal.pone.0243774. View

5.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignass A, Ehehalt R . . Z Gastroenterol. 2022; 60(3):332-418. DOI: 10.1055/a-1713-3941. View